Clinical Research Directory

Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)

Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis

Summary

The objective of this observational study is to evaluate the clinical utility of the combined assay of 3 biomarkers: α-FP, α-FP-L3 and DCP (simultaneously measured by µTASWakoTM i30 automated in vitro diagnostic system) in high-risk subjects to develop this neoplasm. In particular, it aims to: * Evaluate the clinical utility of the combined use of α-FP, α-FP-L3 and DCP in predicting the onset of HEPATOCARCINOMA (HCC); * Evaluate the performance of GALAD and GALADUS scores in the early diagnosis of HCC; * Evaluate the association between the levels of the three biomarkers (individually and in combination with each other) and the stage of HCC

Key Details

Conditions

Interventions

Locations (1)